Physician profile
David B Messinger
NPI 1497719025
$3,592.40
in general payments reported to CMS, 2019-2025
24 companies · $89.99 in 2025
The $89.99 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,639 · 2020: $599 · 2021: $200 · 2022: $40.77 · 2023: $673 · 2024: $352 · 2025: $89.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,045.02 | 2019-2025 | Jot Dx, Aveir, Merlin@Home |
| Astrazeneca Pharmaceuticals LP | $562.98 | 2019-2024 | Farxiga, Brilinta, Saphnelo |
| Baxter Healthcare | $188.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $179.40 | 2019 | |
| Biotronik INC. | $166.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $165.96 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $136.71 | 2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $129.01 | 2019 | |
| Edwards Lifesciences Corporation | $126.04 | 2019 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Abiomed | $114.12 | 2020 | |
| Amgen INC. | $113.54 | 2019-2020 | |
| Inspire Medical Systems, INC. | $111.51 | 2024 | Inspire |
| Boston Scientific Corporation | $95.02 | 2019-2021 | |
| Medtronic Vascular, INC. | $69.08 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.65 | 2019-2020 | |
| Amarin Pharma, INC. | $42.92 | 2020 | |
| Medtronic, INC. | $40.77 | 2023 | Linq II |
| Cardiovascular Systems INC. | $36.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.44 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.21 | 2019 | |
| Chiesi USA, INC. | $18.91 | 2020 | |
| Allergan, INC. | $14.19 | 2019 | |
| Pfizer INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Messinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.